Revvity Reports Strong Q3 Growth, Announces $1 Billion Share Repurchase Program
- Revvity reports Q3 GAAP earnings per share of $0.77, up from $0.08 last year, showcasing strong growth.
- The company announces a new $1 billion share repurchase program to enhance shareholder value and maintain financial strength.
- Revvity’s Diagnostics segment revenue rises by 6%, while Life Sciences revenue declines by 2%, indicating mixed performance across segments.
Revvity Reports Strong Q3 Growth Amid Strategic Developments
Revvity, Inc. announces its third-quarter financial results for the period ending September 29, 2024, revealing significant growth metrics that underscore the company's strong operational performance. The company achieves GAAP earnings per share of $0.77, marking a dramatic increase from $0.08 in the same quarter of the previous year. Additionally, GAAP revenue climbs to $684 million, reflecting a modest year-over-year growth from $671 million. This growth is accompanied by a remarkable surge in operating income from continuing operations, which rises to $98 million, compared to $69 million last year. Revvity’s GAAP operating profit margin also improves to 14.3%, a notable increase from 10.3% in Q3 2023.
In terms of adjusted financials, Revvity posts earnings per share of $1.28, slightly higher than the $1.18 recorded a year earlier. Adjusted operating income also sees a rise to $193 million from $185 million, contributing to an improved adjusted operating profit margin of 28.3%, compared to 27.5% last year. CEO Prahlad Singh expresses optimism about the company's strong cash flow and revenue growth, highlighting their potential impact on advancing science and healthcare. The figures reveal Revvity's ability to navigate a competitive landscape effectively while maintaining operational efficiency.
Segment analysis indicates a mixed performance across Revvity’s business lines. The Life Sciences segment reports revenue of $301 million, down 2% year-over-year, indicating some challenges in this sector. Conversely, the Diagnostics segment experiences a 6% increase in revenue, totaling $383 million. Adjusted operating income for Life Sciences declines to $103 million from $114 million, while Diagnostics sees a significant rise to $101 million, up from $82 million. These results provide insight into the diverse performance within Revvity’s operational portfolio, suggesting areas for potential growth and improvement.
In a strategic move to bolster shareholder value, Revvity's Board of Directors announces a new $1 billion share repurchase program, replacing the previous initiative from May 2023. This decision signals the company's commitment to returning capital to shareholders while maintaining a strong financial position. Furthermore, Revvity plans to host an Investor Day on November 21, 2024, which will be accessible via a live audio webcast, offering investors an opportunity to engage directly with the company's leadership.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

